PHRM 822 Medications List > Schizophrenia > Flashcards

Schizophrenia Flashcards

(163 cards)

Study These Flashcards
1
Q

Negative Symptoms

A

blunted emotion
poor self-care
social withdrawal
poverty in speech

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Positive Symptoms

A

hallucinations
delusions
bizarre behavior
thought disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cognitive Symptoms

A
  • decrease in cognitive function
  • involves D1 receptors and glutamate receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Serotonin Hypothesis of Schizophrenia

A
  • LSD and mescaline were identified as 5HT agonists
  • 5HT2A receptor as mediator of hallucinations
  • antagonism and inverse agonism linked to antipsychotic activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which receptors modulate dopamine release in cortex, limbic region, and striatum

A

5HT2A receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which receptors modulate glutamate release and NMDA receptors

A

5HT2A receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Glutamate Hypothesis of Schizophrenia

A
  • glutamate is major excitatory neurotransmitter
  • phencyclidine and ketamine, noncompetitive inhibitors of NMDA receptors exacerbate psychosis and cognition deficits (increasing symptoms)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dopamine Hypothesis of Schizophrenia

A
  • D2 receptor antagonists
  • dopaminergic agents exacerbate symptoms of schizophrenia
  • increased D2 receptor density in treated and untreated patients
    -D2 receptor antagonists initially increase metabolites in the CNS and later decrease metabolites in the CNS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Major Receptors Antagonized by Antipsychotics

A

Dopamine
D1 like = 1 and 5
D2 like = 2, 3, 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

5HT2A Receptor Antagonists

A

clozapine
olanzapine
risperidone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Older 5HT agents

A

chlorpromazine
haldol
thioridazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Norepinephrine Alpha 1 Blockade Effects

A

hypotension, sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Norepinephrine Alpha 2 Blockade Effects

A

may be helpful in therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Acetylcholine Effects

A

anticholinergic effects
clozapine, thioridazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Histamine Effects

A

H1 Receptor Antagonists

sedation, weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Correlation between binding potency and clinical effectiveness for ________ receptors, therefore more _______ drug target

A

D2; effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Most antipsychotics drugs are receptor _______

A

antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

D2 ____ D1 receptor binding

A

>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

D2 Receptor Antagonist

A

blocks both pre and post-synaptic receptors

at first, Pre-synaptic blocked: increases the synthesis and release of dopamine

when dopamine diffuses back into the presynaptic receptor, it tells the receptor there is way too much dopamine, presynaptic receptor decreases synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dopamine Physiology and Function: Mesolimbic

A

primary therapeutic effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

D2 Receptor occupancy and rate of EPS as functions of plasma risperidone concentration

A

increased concentration of risperidone –> increased D2 occupancy –> increased EPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

EPS

A

extrapyramidal symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Symptoms of EPS

A

dystonia (increased muscle tones)
pseudoparkinsonism (muscle rigidity)
tremor
akathisia (restlessness)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

When does EPS occur?

A

early, days/weeks, reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Drug Therapy for EPS
benztropine, trihexyphenidyl, akineton (anticholinergic) diphenhydramine (antihistamine) amantadine (dopamine release agent) propranolol (used for akathisia)
25
Tardive Dyskinesia
occurs late, months to a year irreversible
26
Symptoms of Tardive Dyskinesia
rhythmic involuntary movements choreiform: irregular purposelessness athetoid: worm like axial hyperkinesias: to and fro movements
27
MOA of Tardive Dyskinesia
unknown
28
Monitoring of Tardive Dyskinesia
AIMS (abnormal involuntary movement scale) check q6months
29
Treatment of Tardive Dyskinesia
prevention 1. reduce dose of current agent 2. change to a different drug 3. eliminate anticholinergic drugs 4. VMAT inhibitors
30
VMAT2 Inhibitors use
newer drug therapies for tardive dyskinesia prevent dopamine from being packaged, decreasing dopamine release
31
Tetrabenazine
VMAT2 for Huntington's chorea
32
Valbenazine
VMAT2 for tardive diskinesia
33
Deutetrabenazine
for tardive diskinesia and huntington's chorea
34
Neuroleptic Malignant Syndrome
serious and rapid; 10% fatility
35
Symptoms of neuroleptic malignant syndrome
EPS symptoms with fever Impaired cognition (agitation, delirium, coma) muscle rigidity
36
Treatment of neuroleptic malignant syndrome
Restore dopamine balance d/c drug use DA agonists, diazepam, or dantrolene
37
Intractable Hiccupts
chlorpromazine
38
Alcohol withdrawal (hallucinations)
haloperidol
39
nausea and vomiting
metoclopramide promethazine
40
potentiation of opiates and sedatives
droperidol
41
Behavioral effects of antipsychotic drugs
unpleasant in normal subjects or reversal of signs and symptoms of psychosis in affected individuals
42
neuroleptic syndrome of antipsychotic drugs
suppress emotions reduce initiative and interest affect may resemble negative syndromes
43
Loss of accomodation, dry mouth, difficulty urinating, constipation
muscarinic cholinoceptor blockade
44
orthostatic hypotension, impotence, failure to ejaculate
alpha adrenoceptor blockade
45
PD, akathasia, dystonias
dopamine receptor blockade
46
tardive dyskinesia cause
supersensitivity of dopamine receptors
47
toxic-confusal state
muscarinic blockade
48
sedation
histamine receptor blockade
49
amenorrhea-galactorrhea, infertility, impotence
dopamine receptor blockade resulting in hyperprolactinemia
50
weight gain
possibly combined H1 and 5HT2c blockade
51
precautions and contraindications of antipsychotics
CV PD epilepsy (clozapine will lower seizure threshold) diabetes (for newer agents)
52
Aliphathic Phenothiazines
chlorpromazine (no longer 1st line therapy)
53
Chlorpromazine Structure
R2: important for potency R10: requires 3 atom chain (allows nitrogen to bind receptor) 2 atom chain = antihistamine
54
Aliphatic Phenothiazines used for H1 antagonist properties
promethazine (also for N/V)
55
piperidine phenothiazines
thioridazine (sedation, hypotension, anticholinergic, many SE)
56
piperazine phenothiazines
fluphenazine (EPS) prochlorperazine (antiemetic) perphenazine (CATIE studies: combo with anticholinergic)
57
Thioxanthines
thiothixene: modest EPS
58
Butyrophenones
haloperidol (EPS) strong D2 block
59
molindone
moderate EPS
60
pimozide
tourette's disease tics, vocalizaitons
61
Atypical/Second Gen Antipsychotics overview
more metabolic problems reduced EPS
62
Clozapine
1st atypical antipsychotic very effective
63
Agranulocytosis in Clozapine
occurs in 1-2% within 6 months (weekly blood monitoring) 2nd or 3rd line therapy
64
Side Effects of Clozapine
anticholinergic, antihistamine reduced D2 potency = decreased movement disorders risk of diabetes
65
Olanzapine
- weight gain - less likely to cause N/V - less likely to cause movement disorders - risk of diabetes
66
Loxapine
- older agent - metabolite= amoxipine - inhibits NET --> antidepressant
67
Quetiapine
- metabolite w/ antidepressant activity - 5HT2a and D2 - low EPS - low antimuscarinic - hypotension (alpha 1) - sedation (h2) - risk of diabetes
68
Risperidone MOA
5HT2A and D3 receptor antagonist
69
Risperidone Pearls
relatively low EPS < 8 mg/day weight gain, sedation
70
Paliperidone (Invega)
9-hydroxyrisperidone
71
Iloperidone
structurally related to risperidone very potent at alpha 1 receptors
72
Ziprasidone MOA
5HT2A, D2, Alpha 1 affinity
73
Ziprasidone Pearls
prolongs QT interval long acting formulation under study
74
Asenapine
5HT2A and D2
75
Lurasidone MOA
5HT2A and D2
76
Lurasidone Pearls
- less weight gain and metabolic effects - fast onset (days without titration) - low doses similar effectiveness to high doses
77
Pimavanserin
inverse agonist 5HT2A PD psychosis
78
Aripiprazole MOA
high affinity for 5HT2 and D2 partial agonist at 5HT1A receptors (used in depression) moderate affinity for D4, alpha, and histamine
79
Side Effects of Aripiprazole
weight gain low risk for D2 effects
80
When is aripiprazole lauroxil given
q4-8 weeks prodrug
81
Brexpiprazole MOA
D2/D3 partial agonist with less akathisia
82
Cariprazine MOA
D2/D3 partial agonist with greater affinity for D3 weak partial agonist activity at 5-HT1A akathisia is high
83
Lumateperone MOA
partial D2 agonist presynaptic receptors/antagonists at postsynpatic receptors (5HT2A antagonist)
84
Key features that define psychotic disorders
delusions: fixed false beliefs that are not amendable to change even with confliction evidence hallucinations disorganized thinking and speech disorgaanized or abnormal motor behavior negative symptoms
85
Disease course in schizophrenia
onset late adolescence to early adulthood men: late teens, early 20s women: late 20s, early 30s
86
Smoking and Antipsychotics
smoking is associated with induction of 1A2 due to hydrocarbons produced and inhaled decreases the serum concentration of 1A2 substrate antipsychotics (olanzapine, asenapine, clozapine, loxapine)
87
Which 3 medications can hasten the onset of schizophrenia, exacerbate symptoms, and reduce time to relapse
marijuana, cocaine, amphetamine
88
Must consider when prescribing antipsychotics
doses per day side effects previous drug therapy cost of drug therapy concomitant drug therapy need for monitoring
89
First line for Schizophrenia
oral antipsychotic drug therapy is generally considered first-line, unless patient presents reasons to consider IM depot drug therapy first
90
Typical Antipsychotics MOA
D2 receptor antagonist efficacy for positive symptoms is similar to atypical antipsychotics
91
Most commonly used typical antipsych
haloperidol: routine and prn
92
EPS in typical antipsych
more eps with higher potency
93
typical antipsych effect on positive, negative, cognitive symptoms
positive: effective negative may worsen cognitive: may worsen
94
Atypical Antipsychotics MOA
D2 antagonism + 5HT2A antagonist
95
Atypical EPS compared to Typical
less EPS, more metabolic side effects
96
Partial Agonists
stabilize dopamine transmission (not too much, not too little) associated with more akathisia than other antipsychotics approved for adjunct treatment of depression (have boxed warning for suicidal thoughts/behavior)
97
Aripiprazole MOA
partial agonist
98
Aripiprazole CYP P450
2D6 and 3A4 substrate
99
Aripiprazole akathisia
moderate
100
Aripiprazole weight gain
low
101
Brexpiprazole MOA
partial agonist
102
Brexpiprazole CYP P450
2D6 and 3A4 substrate
103
Brexpiprazole akathisia
moderate
104
Brexpiprazole weight gain
low-moderate weight gain
105
Cariprazine MOA
partial agonist
106
Cariprazine CYP P450
3A4 substrate
107
Cariprazine akathisia
moderate
108
Cariprazine weight gain
low-moderate
109
-Pines
less D2 antagonism, more 5HT2A antagonism significantly less EPS higher weight gain
110
Asenapine
sublingual and patch QTc prolongation
111
Clozapine
boxed warnings for neutropenia, orthostaisis, bradycardia, syncope, seizures, myocarditis, cardiomyopathy side effects: sedation, weight gain, constipation, hypersalivation, dry mouth, GI hypomotility with obstructive risk QTc
112
Olanzapine
signficant weight gain and sedation high risk metabolic syndrome DRESS warning
113
1A2 Substrates
asenapine clozapine olanzapine
114
Quetiapine
3A4 substrate QTc prolongation weight gaine an sedation boxed warning for suicidal ideation
115
Secuado (Asenapine) Patch Warning
QTc prolongation
116
Secuado (Asenapine) Patch Interactions
UGT and 1A2 substrate reduce dose of patch if given with strong 1A2 inhibitor (fluvoxamine)
117
Clozapine REMS (ON EXAM)
monitoring timelines weekly x6months, biweekly x 6months, then every 4 weeks
118
Olanzapine/Samidorphan (Lybalvi)
Samidorphan is an opioid antagonist with preferential activity at the mu opioid receptor
119
the dones
D2 and 5HT2A antagonists variable EPS and metabolic side effects
120
Iloperidone warning
high risk for othostasis and syncope QTc prolongation
121
Iloperidone CYP interaction
2D6 substrate
122
Lurasidone CYP interaction
3A4 substrate
123
Lurasidone Warnings
suicidal thoughts higher risk for akathisia take with food to incrase bioavailability
124
Ziprasidone warnings
QTc prolongation (contraindication) DRESS warning take with food to increase absorption and bioavailabiltiy
125
Ziprasidone CYP interaction
3A4 and aldehyde oxidase
126
Risperidone and Paliperidone
highest D2 blockade for atypicals highest EPS, moderate metabolic side effects
127
Risperidone CYP interaction
2D6 substrate (minor 3A4)
128
Risperidone SEs
EPS hyperprolactinemia weight gain sedation orthostatis
129
Paliperidone
renally eliminated QTc prolongation
130
Lumateperone
low risk for weight gain or metabolic side effects low risk for eps or akathisia 3A4 substrate
131
Pimavanserin
treatment of hallucinations or delusions in PD inverse agonist and antagonist at the serotonin 5HT2A 3A4 inhibitor
132
Warnings for all Antipsychotics
- boxed warning for increased risk of death in elderly patients treated with antipsychotics for dementia with related behaviors - metabolic adverse effects - eps - risk of somnolence, hypotension, increases risk for falls and fractures
133
Haloperidol Decanoate
given every 4 weeks loading dose: 20x oral dose maintenance: 10x oral dose
134
Risperdal Consta
must supplement with oral risperidone (or another oral antipsychotic) for the first few weeks of treatment (until 3rd injection)
135
Perseris (risperidone)
abdominal subq injection 34A inducers, use 120 mg dose or may need oral supplementation
136
Rykindo (risperidone)
every 2 week IM injection oral dose overlap is shorter than risperdal Consta ( 7 days vs 21 days)
137
Uzedy (risperidone)
abdominal or upper arm subq injection given once monthly or every 2 months
138
Invega Sustenna (paliperidone)
loading dose, then booster q4 weeks starting 5 weeks after loading injection inital loading and booster must be given in deltoid if loading, no need for oral overlap may require dose adjustment in moderate to severe renal impairment
139
Invega Trinza (paliperidone)
may be initiated for a patient who has been on stable monthly (q4week) IM injection of Invega Sustenna at least four stable doses recommended to be given in deltoid not recommended if CrCl<50 mL/min q3months
140
Invega Hafyera (paliperidone)
may be initiated after stable invega sustenna for 4 months or stable invega trniza after one 3 month dose gluteal injection only q6month
141
Zyprexa Relprevv (olanzapine)
PDSS - post dose delirium sedation syndrome REMS
142
Abilify Maintena
must overlap with oral aripiprazole for at least 14 days after first injection deltoid or gluteal
143
Dose Adjustments for P450 Interactiosn: Abilify Maintena
if taking 2D6 or 3A4 inhibitors or 3A4 inducers for more than 14 days as concomitant therapy avoid 3A4 inducers use
144
Abilify Asimtufii (aripiprazole)
every 2 month dosing gluteal injection only continue oral aripiprazole for 2 weeks after first injection
145
Aristada (aripiprazole lauroxil)
overalap with oral aripiprazole for 3 weeks after first injection
146
Aristada Initio (aripiprazole lauroxil)
developed to avoid 21 day oral overlap of antipsychotic avoid in patients who are 2D6 poor metabolizers or with strong 3A4 or 2D6 inhibitors
147
Commonly used immediate release antipsychotic injections
haloperidol, chlorpromazine, fluphenazine
148
Olanzapine IM and benzodiazepine IM
cannot be given at the same time, boxed warning for respiratory depression
149
Loxapine for inhalation
not commonly used for emergencies due to REMS
150
Treatment of Acutre Dystonia
IM anticholinergic now dose (benztropine 2 mg, diphenhydramine 50 mg)
151
Treatment of Drug Induced PD
oral anticholinergic (trihexyphenidyl, diphenhydramien)
152
Treatment of Akathisia
beta blocker (propranolol) benzodiazepine (lorazepam)
153
Treatment of Tardive Dyskinesia
VMAT inhibitors
154
Valbenzine CYP interacgtion
2D6/3A4 substrate QTc prolongation
155
Duetetrabenazine CYP Interaction
2D6 substrate QTc prolongation
156
Neuroleptic Malignant Syndrome
life threatening, medical emergency hyperpyrexia, tachycardia, labile bp muscle rigidity treatment is suspportive future antipsychotic use is not contraindicated
157
metabolic adverse effects
hyper glycemia, hyperlipidemia, hypertension clozapine = olanzapine > quetiapine = risperidone = paliperidone = asenapine = iloperidone = cariprazine = brexpiprazole > ziprasidone = lurasidone = aripiprazone
158
personal family hx monitoring
baseline yearly
159
weight (BMI) metabolic monitoring
baseline 4 weeks 8 weeks 12 weeks every 3 months
160
waist circumference monitoring
baseline yearly
161
BP/A1C monitoring
baseline 12 weeks yearly
162
fasting lipids monitoring
baseline 12 weeks every 5 years
PHRM 822 Medications List
flashcards
Decks in class (17)
# Cards
Brainscape helps you reach your goals faster, through stronger study habits.
© 2026 Bold Learning Solutions. Terms and Conditions